Outpatient parenteral antimicrobial therapy (OPAT), first introduced in 1977, is a patient management strategy whereby antibiotics are administered outside of the acute care setting with the goal of improving the quality and convenience of care while reducing healthcare costs. As such, OPAT is a dominant component of home infusion services.

today, antibiotics account for 132 million OPAT doses and are expected to see an 8.8% compounded annual growth rate from 2016 to 202311,12

OPAT is predominantly administered intravenously via a peripherally inserted central catheter (PICC or PICC line), which must remain in place over several days or weeks. Although undeniably effective, this approach requires extensive coordination of care and can result in multiple medical complications including PICC line site infections, bloodstream infections, PICC line occlusions and blood clots, requiring unscheduled ER and medical visits.

Outpatient infusion services require labor-intensive coordination, professionally-trained medical personnel and significant associated resources. Additionally, home infusion of OPAT is not covered for most Medicare patients so these services can be cost prohibitive and logistically problematic. As a result, Medicare patients that require OPAT are often dependent on infusion centers, clinics, or nursing homes for care. 

the promise of self-administered subcutaneous ceftriaxone

Ceftriaxone is reliable, proven, and the most commonly used antibiotic in the OPAT setting. Given this broad population impact, we have chosen to develop ceftriaxone for subcutaneous infusion to be delivered by a proprietary, on-body delivery system with the goal of providing a more convenient and user-friendly solution.

We believe that an accessible and convenient combination of drug and device delivery has the potential to transform OPAT and the patient experience by providing appropriate patients with an opportunity to manage their own care in the comfort of home without the need for an IV.

the promise of self-administered subcutaneous ceftriaxone

Ceftriaxone is reliable, proven, and the most commonly used antibiotic in the OPAT setting. Given this broad population impact, we have chosen to develop ceftriaxone for subcutaneous infusion to be delivered by a proprietary, on-body delivery system with the goal of providing a more convenient and user-friendly solution.

We believe that an accessible and convenient combination of drug and device delivery has the potential to transform OPAT and the patient experience by providing appropriate patients with an opportunity to manage their own care in the comfort of home without the need for an IV.

An accessible and convenient combination of drug and device delivery has the potential to transform OPAT and the patient experience

11 132 million doses calculated based on IMS 2015 and AMR 2017 data sets.
12 https://www.globenewswire.com/news-release/2016/05/23/842296/0/en/Home-Infusion-Therapy-Market-size-worth-26-3-Billion-by-2023-Global-Market-Insights-Inc.html